Isotopen Technologien Munchen Competitors and Similar CompaniesClear all

Isotopen Technologien Munchen's competitors and similar companies include BioInvent, Inventiva and Pharma Mar.

	Isotopen Technologien Munchen ITM Isotopen Technologien Munchen is a company that develops, produces, and supplies diagnostic and therapeutic radionuclides and radiopharmaceuticals for use in cancer treatment.	BioInvent BioInvent focuses on the discovery and development of antibody-based drugs against cancer.	Inventiva Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases.	Pharma Mar Pharma Mar is a biopharmaceutical company that engages in the discovery and development of marine-derived anticancer drugs.
Founding Date	Founding Date 2004	Founding Date 1997	Founding Date 2011	Founding Date 1986
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech chemicals drug development medical diagnostics oncology pharma	Tags Healthcare biotech drug development medical diagnostics oncology pharma	Tags Healthcare biotech clinical research drug development medical diagnostics oncology pharma	Tags Healthcare Manufacturing & Industrial biotech chemicals drug development home care medical diagnostics oncology pharma
Locations	Locations Garching bei München, DE HQ München, DE	Locations Lund, SE HQ	Locations Daix, FR HQ	Locations Colmenar Viejo, ES HQ Madrid, ES
Employees	Employees 5403% increase	Employees 118	Employees 114	Employees 500
Valuation ($)	Valuation ($) N/A	Valuation ($) 285.9 m	Valuation ($) 231 m	Valuation ($) 1.4 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) kr226.5m (FY, 2025)	Revenue (est.) €4.5m (FY, 2025)	Revenue (est.) €221.4m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods €12.3m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit kr226.6m (FY, 2025)	Gross profit €7.9m (FY, 2025)	Gross profit €232m (FY, 2025)
Net income	Net income N/A	Net income (kr332.9m) (FY, 2025)	Net income (€354.1m) (FY, 2025)	Net income €75m (FY, 2025)